Literature DB >> 26437865

Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72.

Marka van Blitterswijk1, Tania F Gendron1, Matthew C Baker1, Mariely DeJesus-Hernandez1, NiCole A Finch1, Patricia H Brown1, Lillian M Daughrity1, Melissa E Murray1, Michael G Heckman2, Jie Jiang3, Clotilde Lagier-Tourenne3,4, Dieter Edbauer5,6,7, Don W Cleveland3,8, Keith A Josephs9, Joseph E Parisi9, David S Knopman9, Ronald C Petersen9, Leonard Petrucelli1, Bradley F Boeve9, Neill R Graff-Radford10, Kevin B Boylan10, Dennis W Dickson1, Rosa Rademakers11.   

Abstract

The loss of chromosome 9 open reading frame 72 (C9ORF72) expression, associated with C9ORF72 repeat expansions, has not been examined systematically. Three C9ORF72 transcript variants have been described thus far; the GGGGCC repeat is located between two non-coding exons (exon 1a and exon 1b) in the promoter region of transcript variant 2 (NM_018325.4) or in the first intron of variant 1 (NM_145005.6) and variant 3 (NM_001256054.2). We studied C9ORF72 expression in expansion carriers (n = 56) for whom cerebellum and/or frontal cortex was available. Using quantitative real-time PCR and digital molecular barcoding techniques, we assessed total C9ORF72 transcripts, variant 1, variant 2, variant 3, and intron containing transcripts [upstream of the expansion (intron 1a) and downstream of the expansion (intron 1b)]; the latter were correlated with levels of poly(GP) and poly(GA) proteins aberrantly translated from the expansion as measured by immunoassay (n = 50). We detected a decrease in expansion carriers as compared to controls for total C9ORF72 transcripts, variant 1, and variant 2: the strongest association was observed for variant 2 (quantitative real-time PCR cerebellum: median 43 %, p = 1.26e-06, and frontal cortex: median 58 %, p = 1.11e-05; digital molecular barcoding cerebellum: median 31 %, p = 5.23e-10, and frontal cortex: median 53 %, p = 5.07e-10). Importantly, we revealed that variant 1 levels greater than the 25th percentile conferred a survival advantage [digital molecular barcoding cerebellum: hazard ratio (HR) 0.31, p = 0.003, and frontal cortex: HR 0.23, p = 0.0001]. When focusing on intron containing transcripts, analysis of the frontal cortex revealed an increase of potentially truncated transcripts in expansion carriers as compared to controls [digital molecular barcoding frontal cortex (intron 1a): median 272 %, p = 0.003], with the highest levels in patients pathologically diagnosed with frontotemporal lobar degeneration. In the cerebellum, our analysis suggested that transcripts were less likely to be truncated and, excitingly, we discovered that intron containing transcripts were associated with poly(GP) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.33, p = 0.02, and (intron 1b): r = 0.49, p = 0.0004] and poly(GA) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.34, p = 0.02, and (intron 1b): r = 0.38, p = 0.007]. In summary, we report decreased expression of specific C9ORF72 transcripts and provide support for the presence of truncated transcripts as well as pre-mRNAs that may serve as templates for RAN translation. We further show that higher C9ORF72 levels may have beneficial effects, which warrants caution in the development of new therapeutic approaches.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; C9ORF72; Disease modifier; Frontotemporal dementia; Frontotemporal lobar degeneration; Motor neuron disease

Mesh:

Substances:

Year:  2015        PMID: 26437865      PMCID: PMC4655160          DOI: 10.1007/s00401-015-1480-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  31 in total

1.  Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study.

Authors:  Marka van Blitterswijk; Mariely DeJesus-Hernandez; Ellis Niemantsverdriet; Melissa E Murray; Michael G Heckman; Nancy N Diehl; Patricia H Brown; Matthew C Baker; NiCole A Finch; Peter O Bauer; Geidy Serrano; Thomas G Beach; Keith A Josephs; David S Knopman; Ronald C Petersen; Bradley F Boeve; Neill R Graff-Radford; Kevin B Boylan; Leonard Petrucelli; Dennis W Dickson; Rosa Rademakers
Journal:  Lancet Neurol       Date:  2013-09-05       Impact factor: 44.182

2.  Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.

Authors:  Clotilde Lagier-Tourenne; Michael Baughn; Frank Rigo; Shuying Sun; Patrick Liu; Hai-Ri Li; Jie Jiang; Andrew T Watt; Seung Chun; Melanie Katz; Jinsong Qiu; Ying Sun; Shuo-Chien Ling; Qiang Zhu; Magdalini Polymenidou; Kevin Drenner; Jonathan W Artates; Melissa McAlonis-Downes; Sebastian Markmiller; Kasey R Hutt; Donald P Pizzo; Janet Cady; Matthew B Harms; Robert H Baloh; Scott R Vandenberg; Gene W Yeo; Xiang-Dong Fu; C Frank Bennett; Don W Cleveland; John Ravits
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

3.  Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion.

Authors:  Dhruv Sareen; Jacqueline G O'Rourke; Pratap Meera; A K M G Muhammad; Sharday Grant; Megan Simpkinson; Shaughn Bell; Sharon Carmona; Loren Ornelas; Anais Sahabian; Tania Gendron; Leonard Petrucelli; Michael Baughn; John Ravits; Matthew B Harms; Frank Rigo; C Frank Bennett; Thomas S Otis; Clive N Svendsen; Robert H Baloh
Journal:  Sci Transl Med       Date:  2013-10-23       Impact factor: 17.956

4.  Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations.

Authors:  Ian R Mackenzie; Thomas Arzberger; Elisabeth Kremmer; Dirk Troost; Stefan Lorenzl; Kohji Mori; Shih-Ming Weng; Christian Haass; Hans A Kretzschmar; Dieter Edbauer; Manuela Neumann
Journal:  Acta Neuropathol       Date:  2013-10-06       Impact factor: 17.088

5.  Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins.

Authors:  Kohji Mori; Thomas Arzberger; Friedrich A Grässer; Ilse Gijselinck; Stephanie May; Kristin Rentzsch; Shih-Ming Weng; Martin H Schludi; Julie van der Zee; Marc Cruts; Christine Van Broeckhoven; Elisabeth Kremmer; Hans A Kretzschmar; Christian Haass; Dieter Edbauer
Journal:  Acta Neuropathol       Date:  2013-10-17       Impact factor: 17.088

6.  RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention.

Authors:  Christopher J Donnelly; Ping-Wu Zhang; Jacqueline T Pham; Aaron R Haeusler; Aaron R Heusler; Nipun A Mistry; Svetlana Vidensky; Elizabeth L Daley; Erin M Poth; Benjamin Hoover; Daniel M Fines; Nicholas Maragakis; Pentti J Tienari; Leonard Petrucelli; Bryan J Traynor; Jiou Wang; Frank Rigo; C Frank Bennett; Seth Blackshaw; Rita Sattler; Jeffrey D Rothstein
Journal:  Neuron       Date:  2013-10-16       Impact factor: 17.173

7.  Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons.

Authors:  Sandra Almeida; Eduardo Gascon; Hélène Tran; Hsin Jung Chou; Tania F Gendron; Steven Degroot; Andrew R Tapper; Chantal Sellier; Nicolas Charlet-Berguerand; Anna Karydas; William W Seeley; Adam L Boxer; Leonard Petrucelli; Bruce L Miller; Fen-Biao Gao
Journal:  Acta Neuropathol       Date:  2013-07-09       Impact factor: 17.088

8.  Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72.

Authors:  David M A Mann; Sara Rollinson; Andrew Robinson; Janis Bennion Callister; Jennifer C Thompson; Julie S Snowden; Tania Gendron; Leonard Petrucelli; Masami Masuda-Suzukake; Masato Hasegawa; Yvonne Davidson; Stuart Pickering-Brown
Journal:  Acta Neuropathol Commun       Date:  2013-10-14       Impact factor: 7.801

9.  Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.

Authors:  Pietro Fratta; Mark Poulter; Tammaryn Lashley; Jonathan D Rohrer; James M Polke; Jon Beck; Natalie Ryan; Davina Hensman; Sarah Mizielinska; Adrian J Waite; Mang-Ching Lai; Tania F Gendron; Leonard Petrucelli; Elizabeth M C Fisher; Tamas Revesz; Jason D Warren; John Collinge; Adrian M Isaacs; Simon Mead
Journal:  Acta Neuropathol       Date:  2013-07-02       Impact factor: 17.088

10.  Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood.

Authors:  Veronique V Belzil; Peter O Bauer; Mercedes Prudencio; Tania F Gendron; Caroline T Stetler; Irene K Yan; Luc Pregent; Lillian Daughrity; Matthew C Baker; Rosa Rademakers; Kevin Boylan; Tushar C Patel; Dennis W Dickson; Leonard Petrucelli
Journal:  Acta Neuropathol       Date:  2013-10-29       Impact factor: 17.088

View more
  58 in total

1.  Neurodegenerative disease: C9orf72 repeats compromise nucleocytoplasmic transport.

Authors:  Marka van Blitterswijk; Rosa Rademakers
Journal:  Nat Rev Neurol       Date:  2015-11-03       Impact factor: 42.937

2.  The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis.

Authors:  Yingying Zhang; Aaron Burberry; Jin-Yuan Wang; Jackson Sandoe; Sulagna Ghosh; Namrata D Udeshi; Tanya Svinkina; Daniel A Mordes; Joanie Mok; Maura Charlton; Quan-Zhen Li; Steven A Carr; Kevin Eggan
Journal:  Genes Dev       Date:  2018-06-27       Impact factor: 11.361

3.  Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death.

Authors:  Chantal Sellier; Maria-Letizia Campanari; Camille Julie Corbier; Angeline Gaucherot; Isabelle Kolb-Cheynel; Mustapha Oulad-Abdelghani; Frank Ruffenach; Adeline Page; Sorana Ciura; Edor Kabashi; Nicolas Charlet-Berguerand
Journal:  EMBO J       Date:  2016-04-21       Impact factor: 11.598

Review 4.  Disease Mechanisms of C9ORF72 Repeat Expansions.

Authors:  Tania F Gendron; Leonard Petrucelli
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 5.  Biological Spectrum of Amyotrophic Lateral Sclerosis Prions.

Authors:  Magdalini Polymenidou; Don W Cleveland
Journal:  Cold Spring Harb Perspect Med       Date:  2017-11-01       Impact factor: 6.915

Review 6.  The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease.

Authors:  Aaron R Haeusler; Christopher J Donnelly; Jeffrey D Rothstein
Journal:  Nat Rev Neurosci       Date:  2016-05-06       Impact factor: 34.870

Review 7.  RNA-mediated toxicity in C9orf72 ALS and FTD.

Authors:  Zachary T McEachin; Janani Parameswaran; Nisha Raj; Gary J Bassell; Jie Jiang
Journal:  Neurobiol Dis       Date:  2020-08-21       Impact factor: 5.996

8.  The C9ORF72 Gene, Implicated in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, Encodes a Protein That Functions in Control of Endothelin and Glutamate Signaling.

Authors:  Vitalay Fomin; Patricia Richard; Mainul Hoque; Cynthia Li; Zhuoying Gu; Mercedes Fissore-O'Leary; Bin Tian; Carol Prives; James L Manley
Journal:  Mol Cell Biol       Date:  2018-10-29       Impact factor: 4.272

9.  C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins.

Authors:  Yong-Jie Zhang; Tania F Gendron; Jonathan C Grima; Hiroki Sasaguri; Karen Jansen-West; Ya-Fei Xu; Rebecca B Katzman; Jennifer Gass; Melissa E Murray; Mitsuru Shinohara; Wen-Lang Lin; Aliesha Garrett; Jeannette N Stankowski; Lillian Daughrity; Jimei Tong; Emilie A Perkerson; Mei Yue; Jeannie Chew; Monica Castanedes-Casey; Aishe Kurti; Zizhao S Wang; Amanda M Liesinger; Jeremy D Baker; Jie Jiang; Clotilde Lagier-Tourenne; Dieter Edbauer; Don W Cleveland; Rosa Rademakers; Kevin B Boylan; Guojun Bu; Christopher D Link; Chad A Dickey; Jeffrey D Rothstein; Dennis W Dickson; John D Fryer; Leonard Petrucelli
Journal:  Nat Neurosci       Date:  2016-03-21       Impact factor: 24.884

Review 10.  Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene.

Authors:  Xinmei Wen; Thomas Westergard; Piera Pasinelli; Davide Trotti
Journal:  Neurosci Lett       Date:  2016-09-13       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.